Rosetta Biosoftware Licenses Rosetta Resolver Gene Expression Data Analysis System to Serono
Rosetta Biosoftware announced that Serono licensed the Rosetta Resolver(R) system. The Rosetta Resolver system is an enterprise-wide gene expression data analysis system designed to meet the scientific and business requirements of a global gene expression research effort.
“Rosetta Biosoftware is proud to provide Serono with a scalable system that can accommodate its growing gene expression research needs,” said Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware. “Through partnerships with global biotechnology leaders such as Serono, we continue to gain insights for building a flexible, more robust analysis and data management system.”
The Rosetta Resolver system is developed and supported by Rosetta Biosoftware, and is distributed exclusively by Agilent Technologies, Inc.
About the Rosetta Resolver System
The Rosetta Resolver system is a high-capacity data storage, retrieval and analysis solution for gene expression data. The system is ideal for life science research organizations that need to assess compound specificity or toxicity, identify new genes or therapeutic targets or compare and analyze large databases of expression profiles. The Rosetta Resolver system combines flexibility and ease of use with high-performance algorithms to produce an enterprise solution for rapid analysis of gene expression data. The Rosetta Resolver system can accept and analyze data from a wide variety of expression profiling formats, including Agilent DNA microarrays, and applies Rosetta Biosoftware’s proprietary error models to yield quality statistics for every gene expression measurement within the system. These statistics are automatically leveraged by Rosetta Resolver system analysis tools for optimal results. The system is also highly customizable, and includes a Software Development Kit (SDK) for extension and customization.
In addition to Serono, life science research organizations that have licensed the Rosetta Resolver system include many of the top pharmaceutical companies in the world, such as Bristol-Myers Squibb, GlaxoSmithKline, Merck & Co., Inc., Sanofi-Aventis, as well as premier academic institutions such as the Harvard University Center for Genomics Research. Additional information about the Rosetta Resolver system can be found on the Rosetta Biosoftware Web site at www.rosettabio.com .
About Rosetta Biosoftware
Rosetta Biosoftware is a leading provider of enterprise bioinformatics solutions for life science research. Its enterprise software solutions, including the Rosetta Resolver and Rosetta Luminator gene-expression data analysis systems, empower life scientists with advanced, scalable, and easy-to-use analysis platforms that accelerate discovery research. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc. (NYSE:MRK). More information about Rosetta Biosoftware is available at www.rosettabio.com .
Forward-Looking Statements
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Neither Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect the business of Merck & Co., Inc. including, among others, the extent to which Rosetta Inpharmatics’ technology platform can be used in drug discovery programs, uncertainty of market acceptance of Rosetta Inpharmatics’ technologies, ability to compete against existing technologies and those mentioned in the cautionary statements in Item 1 of Merck’s Form 10-K for the year ended Dec. 31, 2003, and in its periodic reports on Form 10-Q and Form 8-K (if any) which are incorporated by reference.
Rosetta Resolver is a registered trademark of Rosetta Inpharmatics LLC.
